Japan Nuclear Medicine Market to Reach US$ 2,543.2 Million by 2031, Growing at a CAGR of 21.2% During 2024-2031 | Key Players: GE Healthcare, Fujifilm, Siemens Healthineers, Bracco, CANON MEDICAL SYSTEMS CORPORATION

The Japan nuclear medicine market reached US$ 550.3 million in 2023 and is expected to reach US$ 2,543.2 million by 2031, growing at a CAGR of 21.2 % during the forecast period 2024-2031.

Japan nuclear medicine is a rapidly evolving sector that utilizes radioactive substances for the diagnosis, treatment, and monitoring of various diseases, including cancer, cardiovascular, and neurological disorders. Techniques such as PET, SPECT, and targeted radionuclide therapy enable precise imaging and personalized treatment planning. Japan's advanced healthcare infrastructure, strong research capabilities, and regulatory support contribute to the growth of nuclear medicine applications. Ongoing innovations in radiopharmaceuticals, imaging technologies, and minimally invasive therapies are enhancing diagnostic accuracy and therapeutic outcomes. With an increasing focus on early detection and precision healthcare, Japan nuclear medicine is playing a pivotal role in improving patient care and clinical efficiency.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/japan-nuclear-medicine-market?praveen

Japan: Recent Industry Developments
✅ In November 2025, Japanese hospitals and diagnostic centers expanded nuclear medicine services with advanced PET, SPECT, and hybrid imaging systems, improving early disease detection and treatment monitoring. This reinforces Japan's leadership in precision diagnostics.

✅ In October 2025, manufacturers introduced high-sensitivity radiopharmaceuticals for targeted imaging and therapy, enhancing diagnostic accuracy and patient outcomes.

✅ In September 2025, collaborations between research institutions and healthcare providers focused on theranostic approaches, combining diagnostics and therapy for oncology and cardiovascular diseases.

✅ In August 2025, Japanese nuclear medicine centers adopted AI-enabled imaging analysis and workflow automation, reducing scan times, optimizing resource use, and improving clinical decision-making.

Global: Recent Industry Developments
✅ In 2025, global nuclear medicine adoption increased due to rising prevalence of cancer, cardiovascular diseases, and neurological disorders, along with growing demand for precision imaging and targeted therapies.

✅ In 2025, international manufacturers launched next-generation radiopharmaceuticals, hybrid imaging systems, and AI-assisted analytics, improving diagnostic accuracy and therapy planning.

✅ In 2024-2025, advancements in molecular imaging, radiotracer development, and imaging automation enhanced global adoption of nuclear medicine in hospitals and research centers.

✅ In 2025, collaborations between nuclear medicine companies, hospitals, and research organizations strengthened innovation pipelines, clinical trial expansion, and distribution networks worldwide.

Key Merges and Acquisitions(2025):
✅ FUJIFILM Toyama Chemical Co., Ltd. - strengthened its nuclear medicine portfolio in 2025 by acquiring a Japan-based radiopharmaceutical startup, enhancing diagnostic imaging and targeted therapeutic solutions for oncology and cardiology.

✅ Sumitomo Pharma - expanded its molecular imaging and nuclear medicine capabilities through the acquisition of a PET/SPECT tracer development company, enabling advanced personalized medicine and improved patient outcomes in Japan.

✅ Japan Nuclear Medicine Consortium - pursued strategic acquisitions in 2025 targeting innovative startups focused on radiopharmaceutical innovation, AI-driven imaging analytics, and theranostics to capture growing demand in the expanding Japanese nuclear medicine market.

Growth Drivers:
- Rising prevalence of cancer, cardiovascular, and neurological diseases in Japan driving demand for diagnostic and therapeutic nuclear medicine procedures.

- Increasing adoption of advanced imaging technologies such as PET, SPECT, and hybrid systems for early detection and precise disease monitoring.

- Growing focus on personalized medicine and targeted radiopharmaceutical therapies enhancing treatment outcomes.

- Advancements in radiotracers, imaging software, and hybrid imaging systems improving accuracy, safety, and efficiency.

- Expanding healthcare infrastructure, government support for advanced diagnostics, and rising investment in nuclear medicine research facilitating broader adoption across clinical settings.

Purchase this report before year-end and unlock an exclusive 30% discount https://www.datamintelligence.com/buy-now-page?report=japan-nuclear-medicine-market?praveen
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis - Japan Nuclear Medicine
- By Product Type
Radiopharmaceuticals lead with around 50% share, driven by their critical role in diagnostic imaging, therapy, and targeted treatment of cancers and cardiovascular diseases. Imaging systems account for approximately 30%, including PET, SPECT, and gamma cameras used in hospitals and diagnostic centers. Other product types represent roughly 20%, such as software, accessories, and ancillary devices supporting nuclear medicine procedures.

- By Procedural Volume Assessment
High-volume diagnostic procedures dominate with 60% share, including oncology scans, cardiac imaging, and bone scintigraphy, reflecting growing demand for early detection and precision diagnostics. Therapeutic procedures account for about 25%, such as targeted radionuclide therapy for cancer and thyroid disorders. Other procedural volumes represent 15%, including research applications and specialized nuclear medicine treatments.

- By Application
Oncology dominates with approximately 50% share, driven by rising cancer prevalence, personalized medicine adoption, and the use of PET/SPECT imaging for tumor detection and therapy planning. Cardiology accounts for around 25%, supported by nuclear imaging for myocardial perfusion and cardiac function assessment. Neurology holds about 15%, used in neurodegenerative disorder diagnosis and brain function studies. Other applications represent 10%, including musculoskeletal, renal, and infectious disease imaging.

Key Players
GE Healthcare, Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), Siemens Healthineers, Bracco, CANON MEDICAL SYSTEMS CORPORATION, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), ATOX CO., Ltd., IBA Radiopharma Solutions, JFE Engineering Corporation, and Koninklijke Philips N.V.

Key Highlights (5 Key Players) for Japan Nuclear Medicine :
- GE Healthcare generates significant revenue in the Japan nuclear medicine market by providing advanced imaging systems, radiopharmaceuticals, and diagnostic solutions, supporting hospitals and clinics with high-precision PET, SPECT, and hybrid imaging technologies.

- Fujifilm (FUJIFILM Toyama Chemical Co. Ltd) drives strong revenue through radiopharmaceuticals and nuclear medicine diagnostic agents, leveraging its pharmaceutical expertise and established healthcare distribution networks in Japan.

- Siemens Healthineers secures substantial revenue from nuclear medicine equipment and solutions, including PET/CT and SPECT systems, integrated software, and service offerings for Japanese hospitals and diagnostic centers.

- Bracco generates consistent revenue from radiopharmaceuticals and imaging agents used in nuclear medicine diagnostics, supporting clinical applications in cardiology, oncology, and neurology across Japan.

- CANON MEDICAL SYSTEMS CORPORATION achieves steady revenue from nuclear medicine imaging systems, offering PET, SPECT, and hybrid modalities with advanced software and workflow solutions tailored for Japanese healthcare providers.

Speak to Our Analyst and Get Customization in the report as per your requirements https://www.datamintelligence.com/customize/japan-nuclear-medicine-market?praveen

Regional Insights - Japan Nuclear Medicine Market
- Japan represents a significant market in Asia-Pacific for nuclear medicine, accounting for approximately 7-9% of the regional market. Growth is driven by increasing prevalence of cancer and cardiovascular diseases, rising demand for diagnostic imaging, and advanced healthcare infrastructure.

- Expansion is supported by high adoption of PET, SPECT, and radiopharmaceutical technologies, growing awareness of early disease detection, and strong government initiatives promoting advanced diagnostic and therapeutic solutions. Leading hospitals and specialized nuclear medicine centers in Japan contribute to the market's steady growth.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.